Q-omics provides the consensus-scored MIR9-3HG profile across patient tissues and cancer cell-line models. MIR9-3HG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR9-3HG is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MIR9-3HG RNA expression shows 15,234 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, and TGCT as cancer lineages where MIR9-3HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR9-3HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR9-3HG survival associations across molecular data types. MIR9-3HG RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR9-3HG RNA expression–survival associations across cancer types. High MIR9-3HG expression shows unfavorable associations in KIRP and ACC, but favorable associations in HNSC, SKCM, LGG and KICH. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR9-3HG RNA expression.
This table summarizes MIR9-3HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR9-3HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR9-3HG shows lower tumor expression in COAD, THCA and KIRP and higher tumor expression in HNSC, LUSC and BLCA. The HNSC box plot shows higher MIR9-3HG RNA expression in tumor versus normal tissue (log2 FC = +0.992, t-test p < 0.001).
This table shows molecular features associated with MIR9-3HG in patient tissues and cancer cell lines. In patient samples, MIR9-3HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
